Search company, investor...

Intelligent Bio-Systems

Founded Year



Acquired | Acquired

Total Raised


About Intelligent Bio-Systems

Intelligent Bio-Systems is developing a next generation DNA sequencing system that aims to simultaneously increase the speed and reduce the cost of producing sequence data.On June 26, 2012, Intelligent Bio-Systems was acquired by QIAGEN. The terms of the transaction were not disclosed.

Headquarters Location

34 Bear Hill Road

Waltham, Massachusetts, 02451,

United States


Missing: Intelligent Bio-Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intelligent Bio-Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Intelligent Bio-Systems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intelligent Bio-Systems is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Intelligent Bio-Systems Patents

Intelligent Bio-Systems has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Chemical tests
  • DNA sequencing
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Biotechnology, DNA, Nucleotides


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Biotechnology, DNA, Nucleotides



Latest Intelligent Bio-Systems News

Massachusetts Life Sciences Center Backs Three Start-ups

Jan 4, 2012

Massachusetts Life Sciences Center Backs Three Start-ups January 4, 2012 The Massachusetts Life Sciences Center announced Wednesday that it has backed three new early-stage life sciences start-ups with a total of $2.2 million in loans. The center’s Accelerator Program recently backed Intelligent Bio-Systems Inc., Allurion Technologies Inc. and Paragonix Technologies Inc. PRESS RELEASE The Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the state’s ten-year, $1 billion Life Sciences Initiative, today announced the awarding of $2.2 million in loans to three early-stage life sciences companies. The Center’s Accelerator Program provides loans of up to $750,000 to early-stage companies engaged in life sciences research and development, commercialization and manufacturing. The Center’s Board of Directors approved the fourth round of Accelerator loans today. The Accelerator Program, the Center’s flagship investment program for companies, supports and “de-risks” early-stage companies by providing loans that will match other sources of capital. By leveraging other sources of capital, the Accelerator Program provides support to companies at the most critical stages of their development cycle, enabling them to conduct vital research and proof-of-concept studies and attract subsequent investment while improving the odds of bringing cutting edge innovation to the marketplace. In September of 2010, Good Start Genetics became the first of these companies to pay back their loan, with interest, after securing $18 million in Series A financing. The company recently moved into 15,000 square feet of space in Cambridge and now has more than 20 employees. In October 2010 Invivo Therapeutics paid back their loan to the Center, with interest, after raising $13 million in private financing. InVivo just announced a lease for 21,000 square feet of space in Cambridge, currently employs 20 people, and has plans to grow to more than 30 employees in the coming year. Loan repayments contribute back to the Center’s funds that are available for reinvestment through this and other programs. Applicants for the Accelerator Program are generally early-stage life sciences companies with a high-potential for technology commercialization, rapid growth, and downstream private equity financing. The loans are designed to address the need for capital investment associated with the  long life sciences R&D cycle and the high cost of translating research into a commercially viable product. Applications were subjected to a double-blind, rigorous peer review, followed by an evaluation by the Center’s Scientific Advisory Board (SAB). Applicants were then further screened by the Center’s Investment Sub-Committee of the Board of Directors, through a process that included a live presentation by finalists. Final awards were determined by the Center’s Board of Directors. The three companies that were authorized today to receive loans (pending due diligence by Center staff) through the Accelerator Program are: Intelligent Bio-Systems, Inc. – $750,000 (Waltham) – A DNA sequencing company with a patented, higher performance, lower cost next generation DNA sequencing instrument and consumable system. The core technology is fully developed, large scale instrument prototypes are functional, and the Company is getting ready to launch a smaller, lower cost highly flexible version of the system. They are currently focused on completing small scale prototypes and moving into beta testing in customer labs. Allurion Technologies, Inc. – $750,000 (Wellesley) – Developing a novel medical device called Allurion designed to induce significant weight loss by displacing volume in the stomach. Leveraging super-porous hydrogel technology enables the device to be delivered without surgery and it can be eliminated via an orally available, non-toxic dissolution agent. Due to the ease of application and removal, the product will target patients across the obesity spectrum. The company is currently focused on testing to pave the way for a first-in-man trial. Paragonix Technologies, Inc. – $710,000 (Cambridge) – Commercializing first-in-class, single- use and highly portable Organ Preservation and Transport Devices called ‘Sherpas.’ The strongly protected IP relies on elasto-mechanical properties of the organ compartment in combination with control elements to harness the energy stored in compressed oxygen. Paragonix has begun with a Sherpa for kidney transport, but is planning to expand their ‘Sherpa’ product line for other organs. They are currently focused on completing product development and regulatory submission. “The Life Sciences Center’s Accelerator Program is creating jobs and driving innovation by helping early-stage life sciences companies grow into larger companies,” said Secretary of Housing & Economic Development Gregory Bialecki, co-chair of the Center’s Board of Directors. “We look forward to working with these companies as they put down roots and grow in Massachusetts, supporting the future of life sciences and medical technology in our own backyard.” “The Center’s Accelerator companies have been making extraordinary progress in attracting private capital, creating jobs and advancing important new medical technologies to the marketplace,” said Massachusetts Life Sciences Center President and CEO, Dr. Susan Windham- Bannister. “We are pleased to add these three promising companies to the Center’s investment portfolio.” “The Center’s Accelerator loan has provided Grove Instruments with significant capital for critical projects and a substantial amount of recognition in the greater MedTech community,” said Arthur Combs, CEO of Worcester-based Grove Instruments, which received an Accelerator loan earlier this year. “AesRx is developing a therapeutic for sickle cell which is an orphan disease,” said Stephen Seiler, CEO of Newton-based AesRx, which received an Accelerator loan earlier this year. “To secure funding for any early stage drug program in today’s environment is difficult – doubly so for an orphan indication. The Massachusetts Life Sciences Center’s support was critical in getting us from pre-clinical development into human trials.” About the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (“the Center”) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit About the Life Sciences Accelerator Program In order to expand life sciences-related employment opportunities, promote health-related innovations and stimulate research and development, manufacturing and commercialization in the life sciences, the Life Sciences Accelerator Program provides loans to companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Target entities are generally early-stage life sciences companies with a high-potential for technology commercialization, rapid growth, and downstream private equity financing. The program is designed to help sustain these companies through a critical stage of development and to leverage additional sources of capital to bring cutting edge innovation to the marketplace. © 2015 Buyouts Insider / Argosy Group LLC

Intelligent Bio-Systems Frequently Asked Questions (FAQ)

  • When was Intelligent Bio-Systems founded?

    Intelligent Bio-Systems was founded in 2005.

  • Where is Intelligent Bio-Systems's headquarters?

    Intelligent Bio-Systems's headquarters is located at 34 Bear Hill Road, Waltham.

  • What is Intelligent Bio-Systems's latest funding round?

    Intelligent Bio-Systems's latest funding round is Acquired.

  • How much did Intelligent Bio-Systems raise?

    Intelligent Bio-Systems raised a total of $11.27M.

  • Who are the investors of Intelligent Bio-Systems?

    Investors of Intelligent Bio-Systems include QIAGEN, Massachusetts Life Sciences Center, National Institutes of Health, Hub Angels Investment Group, Qualifying Therapeutic Discovery Project and 3 more.

  • Who are Intelligent Bio-Systems's competitors?

    Competitors of Intelligent Bio-Systems include Nabsys, DNAnexus, CombiMatrix, CLC bio, Complete Genomics and 12 more.

Compare Intelligent Bio-Systems to Competitors

Nabsys Logo

Nabsys develops an electronic mapping solution for the analysis of genomic structural information. It offers solutions for genome assembly, structural variation, strain identification, and sample preparation. The company was founded in 2005 and is based in Providence, Rhode Island.

DNAnexus Logo

DNAnexus, a multiomics platform, is creating scalable and collaborative data technologies to unlock the potential of DNA-based medicine and biotechnology. The company has created a cloud-based DNA data management and biomedical data analysis platform that provides instant online genomics data centers for researchers and sequencing service providers alike.

Gene Pass

Gene Pass offers DNA sequencing, synthetic genes, and cloning services

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Functional Biosciences

Functional Biosciences specializes in genomics research. The company produces reagents and an informatics tools, and aims to provide services that simplify preclinical drug development, reduce the costs of toxicity screening, improve the efficiency of DNA sequencing, and more.


Employing recent advances in sequencing, ASPE bead array, microarray technology, Q'Array is poised to provide a range of DNA testing, including genetic, chromosomal, biochemical, pharmacogenomics, paternity, and forensic identity testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.